When developing novel life science technologies, drugs, biologics, and gene or cell therapies, how often do early-stage teams conduct a structured evaluation of preclinical-stage targets, or a meaningful sense-check of what CTA/IND readiness actually looks like?
In many organisations, the answer is: not early enough.
Early-stage development teams are often running scientific, CMC, translational, and clinical workstreams in parallel, converging those efforts into the eventual eCTD components of a submission. The science may be strong. The platform may be compelling. The data package may appear technically sufficient.
But the regulatory structure and strategic narrative are frequently retrofitted after the work has already begun rather than designed in parallel with the science itself.
In practice, many teams are preparing the dossier — but not necessarily preparing the pathway to licensure.
The Difference Between a Submission and a Strategy
There is an important distinction between compiling information for an IND/CTA submission and building an integrated regulatory pathway capable of supporting long-term development success.
The former is document-focused:
- assembling studies
- generating reports
- preparing manufacturing data
- formatting modules
- completing submission requirements
The latter is pathway-focused:
- identifying critical uncertainties early
- understanding regulatory expectations before they become obstacles
- sequencing evidence strategically
- evaluating platform-specific risks
- anticipating policy and precedent considerations
- designing development plans that remain viable beyond the first filing
Many programmes are technically active but strategically under-integrated.
The result is that development decisions made upstream — during target selection, platform development, analytical characterisation, process design, or translational planning — may later create downstream regulatory friction that is significantly more difficult and expensive to resolve.
The Risk Is Usually Not Visible Early
One of the biggest challenges in early-stage development is that regulatory risk often remains largely invisible until relatively late in the process.
Gaps rarely emerge during internal programme reviews. They tend to surface when programmes encounter external scrutiny:
- at a pre-CTA or pre-IND meeting
- during a health authority review
- in response to agency questions
- during manufacturing scale-up
- through comparability challenges
- or deep into pivotal development
By that stage, timelines are tighter, programmes are more expensive, and strategic flexibility is significantly reduced.
What initially appeared to be manageable technical uncertainties can rapidly compound into:
- delayed submissions
- additional studies
- expanded comparability requirements
- manufacturing remediation
- revised clinical strategies
- increased capital requirements
- or programme delays that materially affect development momentum
In many cases, these are not failures of science. They are failures of early strategic integration.
Why This Is Increasingly Important
The complexity of modern therapeutic development continues to expand.
Cell therapies, gene therapies, RNA technologies, personalised medicines, platform technologies, AI-enabled products, and novel manufacturing systems are challenging traditional regulatory paradigms. In parallel, regulatory expectations around CMC robustness, analytical characterisation, platform consistency, real-world evidence, and lifecycle planning are becoming more sophisticated.
This creates an environment where early assumptions matter more than ever.
A development strategy that works for a conventional small molecule programme may not translate effectively to:
- autologous therapies
- decentralised manufacturing models
- platform biologics
- synthetic biology applications
- or adaptive platform technologies
The consequence is that regulatory strategy can no longer function as a downstream compliance activity. It must become part of the architecture of development itself.
Building the Pathway Alongside the Science
The strongest programmes increasingly treat regulatory strategy as an integrated development discipline rather than a submission-stage activity.
This does not mean slowing innovation. It means shaping innovation in ways that remain durable under regulatory scrutiny.
That includes:
- identifying critical path uncertainties early
- stress-testing development assumptions
- evaluating precedents and policy trends
- understanding where evidence expectations may evolve
- aligning CMC and clinical sequencing
- anticipating scalability challenges
- and engaging regulators before constraints harden into obstacles
Importantly, this work is not purely regulatory. It directly affects:
- programme feasibility
- development timelines
- operational flexibility
- manufacturing readiness
- resource allocation
- and ultimately patient access
Mechanisms Teams Should Be Using Earlier
Health authorities increasingly recognise the need for earlier scientific and technical engagement, particularly for novel or accelerated programmes.
Several mechanisms already exist to support this. A few examples include:
FDA CDRP (CMC Development and Readiness Pilot)
Supports structured CMC dialogue for programmes operating on expedited development timelines, helping teams identify manufacturing and readiness challenges earlier.
FDA Emerging Technology Team (ETT)
Facilitates engagement around novel manufacturing technologies, advanced platforms, and non-traditional production approaches.
CBER Advanced Technologies Team (CATT)
Provides scientific interaction for emerging technologies relevant to biologics and advanced therapeutic products.
INTERACT Meetings
Supports early-stage discussions for innovative products before formal pre-IND engagement, particularly useful for highly novel therapeutic approaches.
EMA Innovation Task Force (ITF)
Provides early engagement opportunities between developers and the European regulatory network for emerging technologies and innovative products.
EMA PRIME
Supports medicines addressing unmet medical needs through earlier and more coordinated regulatory interaction.
These mechanisms are often underutilised — particularly by early-stage organisations that may not yet have embedded regulatory strategy deeply into programme planning.
When used proactively, however, they can significantly improve development clarity and reduce uncertainty before programmes become operationally constrained.
Preparing the Pathway, Not Just the Filing
One of the most common misconceptions in early development is that regulatory strategy begins shortly before submission.
In reality, the most consequential regulatory decisions are often made much earlier:
- during platform selection
- during process development
- during analytical design
- during translational planning
- during evidence prioritisation
- and during the earliest assumptions about scalability and manufacturability
By the time a dossier is assembled, much of the strategic trajectory has already been locked in.
That is why the most effective development teams do not simply prepare for filing. They prepare for the full pathway to licensure from the beginning.
Because the real objective is not submitting an IND or CTA.
The objective is building a programme capable of surviving the increasingly complex path that follows.